Physician profile
Ashley Odukoya
NPI 1225554033
$1,872.75
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $161 · 2021: $128 · 2022: $839 · 2023: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $444.28 | 2020-2023 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $353.39 | 2021-2023 | |
| Lilly USA, LLC | $198.29 | 2022-2023 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $142.77 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $96.58 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $96.13 | 2022-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.95 | 2021-2023 | Tradjenta, Jardiance |
| Pfizer INC. | $76.93 | 2022-2023 | |
| Glaxosmithkline, LLC. | $72.23 | 2022-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.92 | 2021-2023 | Xifaxan |
| Exact Sciences Corporation | $41.70 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $41.07 | 2022 | |
| Merck Sharp & Dohme LLC | $39.40 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.00 | 2022-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $27.80 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $25.86 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.69 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $14.45 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.37 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Odukoya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.